Daicel (TSE:4202) One Off ¥19.0b Loss Challenges Bullish Earnings Narratives

Daicel (TSE:4202) FY 2026 earnings: sharp Q4 hit after steady revenue run Daicel (TSE:4202) has just wrapped up FY 2026 with Q4 revenue of ¥154,805 million and a basic EPS loss of ¥99.10, capping a year where trailing 12 month revenue was ¥579,629 million and basic EPS was ¥38.74. Over recent periods the company has seen quarterly revenue move from ¥153,986 million in Q4 FY 2025 to ¥139,270 million in Q1 FY 2026, ¥137,849 million in Q2 and ¥147,705 million in Q3, while basic EPS shifted from ¥20.40 to ¥36.28, ¥34.61 and ¥64.26 before the latest loss. With a reported one off hit of ¥19.0 billion pulling the trailing net margin down to 1.8% from 8.4% a year earlier, investors are likely to focus on how profitability develops from here. See our full analysis for Daicel.With the headline numbers on the table, the next step is to see how these results line up with the prevailing narratives around Daicel's growth potential, risks and valuation signals. Curious how numbers become stories that shape markets? Explore Community Narratives TSE:4202 Revenue & Expenses Breakdown as at May 2026 ¥19.0b one off loss pulls full year profit down to ¥10.2b Over the last 12 months Daicel generated ¥579,629 million in revenue and ¥10,180 million in net income, with the ¥19.0b one off loss leaving the net margin at 1.8% compared with 8.4% in the prior year. Bulls often point to the scale of the broader business, and the data here shows why that view is tested, with revenue of about ¥580b and positive net income still recorded despite the ¥19.0b hit. However, margins over the same period sit at 1.8% rather than the 8.4% previously achieved. Trailing P/E of 29x vs industry at 14.3x Daicel trades on a trailing P/E of 29x, which is higher than both the JP Chemicals industry average of 14.3x and the peer average of 16x, even though reported net margin over the last year was 1.8% after the one off loss. What stands out for a cautious, more bearish take is that valuation multiples are elevated while profitability is thinner. The 29x P/E sits above industry and peers, yet the same trailing period includes the ¥19.0b one off loss and a lower 1.8% margin, so anyone arguing the stock already prices in strong fundamentals has to weigh that against the compressed trailing profitability. Share price at ¥1,157 vs DCF fair value of ¥4,885.17 The current share price of ¥1,157 sits well below the stated DCF fair value of ¥4,885.17, while analysts’ earnings forecasts in the data point to about 33.3% expected annual earnings growth over the next three years and revenue growth of 5.4% a year. Supporters of a more bullish stance highlight this wide gap to DCF fair value and the 33.3% expected earnings growth. However, the same dataset also flags a high level of debt and a 5.19% dividend that is not clearly covered by free cash flow, which means the optimistic view has to account for both the potential upside in valuation models and the balance sheet and payout pressures being carried today. 📊 Read the what the Community is saying about Daicel.Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Daicel's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. The mix of risks, rewards and valuation gaps here will feel very different depending on your priorities, so take a moment to review the full picture, pressure test each data point for yourself, then weigh it against the 2 key rewards and 4 important warning signs. See What Else Is Out There Daicel combines a high 29x P/E and thin 1.8% net margin with a one off ¥19.0b loss and a dividend that is not clearly covered by free cash flow. If you are uneasy about that mix of earnings pressure and payout strain, use the solid balance sheet and fundamentals stocks screener (36 results) to quickly zero in on companies with sturdier financial foundations and clearer cash coverage. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free